Adaptimmune Therapeutics Shares Are Trading Higher After the Company and Galapagos Entered a Clinical Collaboration to License Adaptimmune's Uza-cel in in Head & Neck Cancer.
Adaptimmune Therapeutics Shares Are Trading Higher After the Company and Galapagos Entered a Clinical Collaboration to License Adaptimmune's Uza-cel in in Head & Neck Cancer.
Adaptimmune Therapeutics與加拉帕戈斯達成臨床合作，授權Adaptimmune旗下的Uza-Cel進入頭頸癌領域，此後，該公司股價走高。
Adaptimmune Therapeutics Shares Are Trading Higher After the Company and Galapagos Entered a Clinical Collaboration to License Adaptimmune's Uza-cel in in Head & Neck Cancer.
Adaptimmune Therapeutics與加拉帕戈斯達成臨床合作，授權Adaptimmune旗下的Uza-Cel進入頭頸癌領域，此後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。